false
0001585608
0001585608
2024-08-13
2024-08-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2024
JAGUAR HEALTH, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
001-36714 |
46-2956775 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
200 Pine Street, Suite 400
San Francisco, California |
94104 |
| (Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (415) 371-8300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common Stock, Par Value $0.0001 Per Share |
JAGX |
The Nasdaq Capital Market |
Item 2.02 Results of Operations and Financial
Conditions.
On August 13, 2024, Jaguar Health, Inc. (the “Company”)
issued a press release announcing second quarter 2024 results. A copy of this press release is furnished as Exhibit 99.1 to this
report.
The information in Item 2.02 and the press release furnished as Exhibit 99.1
hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that section, or incorporated by reference into any of the Company’s
filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in any such filing.
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
JAGUAR HEALTH, INC. |
| |
|
| |
By: |
/s/ Lisa A. Conte |
| |
|
Name: |
Lisa A. Conte |
| |
|
Title: |
President and Chief Executive Officer |
Date: August 13, 2024
Exhibit 99.1
Jaguar Health
Reports Second Quarter 2024 Financial Results
The combined net Q2 2024 revenue of approximately
$2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and
2.0% versus net Q2 2023 revenue of $2.67 million
Company to complete analysis of full data for
first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea
(CTD) in support of FDA discussion; Jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase
3 results
Jaguar planning to begin commercial launch
in October 2024 for Gelclair®, the company’s third prescription product
Import permit for crofelemer granted for independent,
investigator-initiated proof-of-concept trial in Abu Dhabi in pediatric patients for the rare and orphan disease indications of microvillus
inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure
REMINDER: Jaguar to host investor
webcast Tuesday, August 13th at 8:30 a.m. Eastern regarding Q2 2024 financials and company updates; Click here
to register for webcast
SAN FRANCISCO,
CA / August 13, 2024 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”)
today reported its consolidated second-quarter 2024 financial results and provided Company updates.
The combined net revenue for the Company’s crofelemer prescription
products, Mytesi® and Canalevia®-CA1, and the Company’s non-prescription products,
was approximately $2.72 million in the second quarter of 2024, representing an increase of approximately 16% over the combined net revenue
in the first quarter of 2024, which totaled approximately $2.35 million, and 2.0% over the combined net revenue in the second quarter
of 2023, which totaled approximately $2.67 million.
Jaguar, with strong leadership and participation from Jaguar family
companies Napo Pharmaceuticals and Napo Therapeutics, is supporting investigator-initiated proof-of-concept (POC) studies
of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal
failure in the US, EU, and Middle East/North Africa (MENA) regions, with results expected by the end of 2024 and throughout 2025. The
import permit for crofelemer for Abu Dhabi for the POC study in pediatric patients with MVID or SBS with intestinal failure has been
granted. In accordance with the guidelines of specific EU countries, published data from clinical investigations in such rare diseases
could support early patient access to crofelemer for these debilitating conditions in those countries.
Lisa Conte,
Jaguar's president and CEO, said, “Our paramount near-term activities are our planned October 2024 commercial launch of the FDA-approved
oral mucositis prescription product Gelclair® in the U.S., progressing our rare disease development business, and our
ongoing analysis of full data for the first and second 12-week stages of our pivotal phase 3 OnTarget trial of crofelemer
for prophylaxis of cancer therapy-related diarrhea (CTD). As announced, we are collaborating with our clinical and scientific
advisers to evaluate the significance of the clinically meaningful results identified in patients with breast and lung cancer in the
initial data from OnTarget, as we plan to engage in discussions with the FDA to explore the possible pathway of approval to make crofelemer
available to breast and lung cancer patients for CTD.”
According
to the World Health Organization, in 2022 breast cancer was the most common cancer in women in 157 countries out of 185, with 2.3 million
women diagnosed with breast cancer globally.1 Lung cancer is the most common cancer worldwide, with 2,480,675 new cases
of lung cancer in 2022. It is the most common cancer in men and the second most common in women.2
2024 SECOND QUARTER COMPANY FINANCIAL RESULTS:
| · | Net Mytesi Revenue: The combined net revenue for Mytesi was approximately $2.64 million in the second quarter of 2024, representing
an increase of approximately 15% over the combined net revenue in the first quarter of 2024, which totaled approximately $2.35 million,
and an increase of 1% over the combined net revenue for the second quarter of 2023, which totaled approximately $2.62 million. |
| · | Mytesi Prescription Volume: Mytesi prescription volume increased in
the second quarter of 2024 compared to the first quarter of 2024 by 5.2%. Prescriptions decreased by 0.4% in the second quarter of 2024
compared to the second quarter of 2023. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying
buying patterns among specialty pharmacies in the closed network as they manage their inventory levels. |
| · | Neonorm™:
Revenues for the non-prescription Neonorm products were minimal for the second quarters of
2024 and 2023. |
| | |
Three Months
Ended | | |
| | |
| |
| Financial Highlights | |
June
30, | | |
| | |
| |
| (in thousands, except per share amounts) | |
2024 | | |
2023 | | |
$
change | | |
%
change | |
| Net product revenue | |
$ | 2,720 | | |
$ | 2,676 | | |
| 44 | | |
| 2 | % |
| Loss from operations | |
$ | (7,198 | ) | |
$ | (8,102 | ) | |
| 904 | | |
| -13 | % |
| Net loss attributable to common
shareholders | |
$ | (9,492 | ) | |
$ | (12,150 | ) | |
| 2,658 | | |
| -28 | % |
| Net loss per share, basic and
diluted | |
$ | (4.04 | ) | |
$ | (41.35 | ) | |
| 37 | | |
| -924 | % |
| · | Cost of Product Revenue: Total cost of product revenue decreased by
approximately $70,000 from $0.50 million for the quarter ended June 30, 2023 compared to $0.43 million for the quarter ended June 30,
2024 |
| · | Research and Development: The R&D expense decreased by $0.6 million,
from $4.3 million for the quarter ended June 30, 2023 to $3.7 million during the same quarter in 2024, primarily due to the winding down
of activities related to the phase 3 OnTarget clinical trial, regulatory activities for the trial,
and the Company’s initiatives for rare disease product development. |
| · | Sales and Marketing: The Sales and Marketing expense decreased by
approximately $0.1 million, from $1.6 million for the quarter ended June 30, 2023 to $1.5 million during the same quarter in 2024. Direct
marketing fees and expenses decreased due to continued savings associated with the utilization of a more cost-effective patient support
services vendor, other Mytesi marketing initiatives, as well as decreased stock-based compensation, and commission expenses. |
| · | General and Administrative: The G&A expense decreased by $0.1
million, from $4.4 million for the quarter ended June 30, 2023, to $4.3 million during the same quarter in 2024, due to decreases in personnel
and benefits, rent and lease, stock-based compensation, travel and other expenses. However, this decrease is offset by an increase in
consulting, audit, tax and accounting services, and public company expenses. |
| · | Loss from Operations: Loss from operations decreased by $0.9 million,
from $8.1 million in the quarter ended June 30, 2023 to $7.2 million during the same period in 2024. |
| · | Net Loss: Net loss attributable to common shareholders decreased by
approximately $2.6 million, from $12.1 million in the quarter ended June 30, 2023 to $9.5 million in the same period in 2024. In addition
to the loss from operations: |
| o | Interest expense decreased by $3.3 million from ($0.11) million in the quarter
ended June 30, 2024 versus $3.5 million for the same period in 2023, primarily due to certain debt instruments being accounted for using
the fair value option. The lower interest expense was offset with a higher loss on change in fair value of debt instruments. |
| o | Change in fair value of financial instrument and hybrid instrument designated
at FVO increased by $1.0 million from a loss of $1.8 million in the three months ended June 30, 2024 compared to a loss of $0.8 million
for the same period in 2023 primarily due to fair value adjustments in liability classified warrants and notes payable designated at FVO. |
| · | Non-GAAP Recurring EBITDA: Non-GAAP recurring EBITDA for the second
quarter of 2024 and the second quarter of 2023 were a net loss of $8.8 million and $7.7 million, respectively. |
| | |
Three
Months Ending | |
| | |
June
30, | |
| (in
thousands) | |
2024 | | |
2023 | |
| | |
| | |
| |
| | |
(unaudited) | |
| Net
loss attributable to common shareholders: | |
$ | (9,492 | ) | |
$ | (12,150 | ) |
| Adjustments: | |
| | | |
| | |
| Interest
expense | |
| (108 | ) | |
| 3,453 | |
| Property
and equipment depreciation | |
| 17 | | |
| 20 | |
| Amortization
of intangible assets | |
| 430 | | |
| 484 | |
| Share-based
compensation expense | |
| 387 | | |
| 529 | |
| Non-GAAP
EBITDA | |
| (8,766 | ) | |
| (7,665 | ) |
| Non-GAAP
Recurring EBITDA | |
$ | (8,766 | ) | |
| (7,665 | ) |
Note Regarding Use of Non-GAAP Measures
The Company supplements its condensed consolidated financial
statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under
applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information
that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in
accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes
for, or superior to, measures of financial performance in conformity with GAAP.
The Company defines non-GAAP EBITDA as net loss before interest expense
and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision
for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring
revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar’s
performance and provide useful information to investors regarding the Company’s results of operations and financial condition.
Participation Instructions for Webcast
When: Tuesday, August 13, 2024, at 8:30 AM Eastern
Time
Participant
Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations
section of Jaguar’s website: (click here)
About Crofelemer
Crofelemer
is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark
sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established
a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity,
and support for Indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals
company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people
and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating
diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and
commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms
across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi® for the
symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics
is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically
for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar
and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription
medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program
at makecancerlessshitty.com and on X, Facebook & Instagram
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic
relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment
of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered,
there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical
studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis
(3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer,
the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton
lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree
of quality and ecological integrity.
About Gelclair®
INDICATIONS
GELCLAIR® has a mechanical action indicated for the
management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including
oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused
by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.
IMPORTANT SAFETY INFORMATION
| · | Do not use GELCLAIR if there is a known or suspected hypersensitivity to
any of its ingredients. |
| · | No adverse effects have been reported in clinical trials, although postmarketing
reports have included infrequent complaints of burning sensation in the mouth. |
| · | If GELCLAIR is swallowed accidentally, no adverse effects are anticipated. |
| · | If no improvement is seen within 7 days, a physician should be consulted. |
You are encouraged to report negative side effects of prescription
medical products to the FDA.
Visit www.fda.gov/safety/medwatch, call 1-855-273-0468 or fill-in
the form at this link.
Please see full Prescribing Information at:
https://gelclair.com/assets/Gelclair_PI_Decemeber_2021.pdf
Important Safety Information About Canalevia®-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1
(crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental
ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious
etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in
dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the
order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed
in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
See full Prescribing Information at Canalevia.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding Jaguar’s expectation that it will host an investor webcast on August 13, 2024,
the Company’s expectation that it will begin the commercial launch in October 2024 for Gelclair, Jaguar’s expectation that
the Company may engage in discussions with the FDA after evaluating the significance of the clinical outcome signals from the OnTarget
trial, Jaguar’s expectation that an approval pathway may exist to make crofelemer available to breast and lung cancer patients for
CTD, the Company’s expectation that results from investigator-initiated and IND proof-of-concept studies of crofelemer for MVID
and SBS with intestinal failure will be available by the end of 2024 and throughout 2025, and the Company’s expectation, that in
accordance with the guidelines of specific EU countries, published data from clinical investigations of crofelemer in MVID and SBS could
support early patient access to crofelemer for these conditions in those countries. In some cases, you can identify forward-looking statements
by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,”
“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,”
“believe,” “estimate,” “predict,” “potential” or “continue” or the negative
of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these
forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak
only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted
or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly
update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances
or otherwise.
1 https://www.who.int/news-room/fact-sheets/detail/breast-cancer
2 https://www.wcrf.org/cancer-trends/lung-cancer-statistics/
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
v3.24.2.u1
Cover
|
Aug. 13, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Aug. 13, 2024
|
| Entity File Number |
001-36714
|
| Entity Registrant Name |
JAGUAR HEALTH, INC.
|
| Entity Central Index Key |
0001585608
|
| Entity Tax Identification Number |
46-2956775
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
200 Pine Street
|
| Entity Address, Address Line Two |
Suite 400
|
| Entity Address, City or Town |
San Francisco
|
| Entity Address, State or Province |
CA
|
| Entity Address, Postal Zip Code |
94104
|
| City Area Code |
415
|
| Local Phone Number |
371-8300
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common Stock, Par Value $0.0001 Per Share
|
| Trading Symbol |
JAGX
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Jaguar Health (NASDAQ:JAGX)
過去 株価チャート
から 7 2024 まで 8 2024
Jaguar Health (NASDAQ:JAGX)
過去 株価チャート
から 8 2023 まで 8 2024
